Clinical trial · Observational
Nimotuzumab in Children With HGG
Phase-II-Study of Efficacy of OSAG 101 (Theraloc®) for Adolscent Patients With Recurrent High Grade Glioma
NCT00561873CI-TRIAL-00000991completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Determination of efficiency of nimotuzumab in children with high grade glioma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| High Grade Glioma | High-Grade Glioma, NOS | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Response rate according to RECIST criteria
- timeFrame
- week 8, week 21
Secondary outcomes (1)
- measure
- Progress free interval, Toxicity according to CTC criteria, Symptom control
- timeFrame
- week 8, week 21
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 3 Years
- Maximum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed diagnosis of high grade glioma (WHO III und IV) \[not needed for intrinsic pontine glioma\] * Progressive patients under primary therapy or first and second radiologically confirmed recurrence(MRI not older than 2 weeks) of high grade gliomas between the age of \> 3 years \< 20 years * Lack of curative standard therapy which is currently under investigation in a national GPOH-therapy optimization study * Sufficient haematological, renal and hepatic function (CTC Grad ≤ 2) * Disease measurable radiologicaly in at least one dimension * Life expectancy \> 4 Weeks * Written declaration of consent of the parents/legal guardians and if possible of the child after prior information Exclusion Criteria: * Curative therapy with an alternative method after diagnosis of progression and during this study * Prior administration of human or murine antibody * Pregnancy in girls of child-bearing age
References
Publications (0)
Data not yet available
No reference posted for this study.